Market Overview
The Shanghai and Shenzhen stock exchanges opened with a broadly positive tone on 27 November 2025. The market saw a sharp rebound after a period of volatility, with the CSI 300 index gaining 1.02 % and the ChiNext index climbing 2.14 %. In total, 4300 shares rose on the day, reflecting widespread buying pressure across the market.
Anti‑Flu Sector Performance
The anti‑flu theme has dominated market sentiment in recent days, driven by data from the China Center for Disease Control and Prevention indicating a rapid rise in influenza‑like illness (ILI) cases. On 26 November the ILI % in northern provinces reached 7.0 %, up from 6.2 % the week before and higher than the corresponding periods in 2022‑24.
In response, a number of anti‑flu stocks have recorded significant gains. On 26 November, Guangji Pharmaceutical achieved a three‑day consecutive limit‑up, Hainan Haiya posted a two‑day limit‑up, and Beida Medical hit a limit‑up on the same day. Yue Wan Nianqing rose more than 11 %. Teyi Pharmaceutical Group Co. Ltd. (ticker: TEYI) also joined the rally, achieving a limit‑up on 27 November and maintaining the rise into the close. Other names such as Jin Dike, Hengdi Pharmaceutical, Zhongsheng Pharmaceutical, and Xinhua Pharmaceutical were also reported to have gained or hit the limit.
Teyi Pharmaceutical’s Activity
TEYI recorded a limit‑up on 27 November, its third trading day within a two‑day period. The share price closed at CNY 13.61 on 25 November, within a 52‑week range of CNY 6.86 to CNY 15.21. The company’s market capitalization is CNY 6.8 billion. The price‑to‑earnings ratio stands at 74.78.
The surge in TEYI’s stock price aligns with the broader anti‑flu rally, as the company is a producer of traditional Chinese medicine and chemical agents. Market participants appear to be betting on increased demand for antiviral therapies and related products amid the heightened influenza activity.
Broader Market Impact
The anti‑flu rally has contributed to the overall market momentum. Several other sectors, including AI, high‑performance computing, and optical communications, also experienced gains. Nevertheless, the most pronounced move was observed in the healthcare and pharmaceutical space, underscoring the influence of macro‑level health data on investor behavior.
Fundamental Snapshot
| Item | Value |
|---|---|
| Close Price (25 Nov 2025) | CNY 13.61 |
| 52‑Week High | CNY 15.21 |
| 52‑Week Low | CNY 6.86 |
| Market Capitalisation | CNY 6.8 billion |
| Price‑to‑Earnings Ratio | 74.78 |
| Primary Exchange | Shenzhen Stock Exchange |
| Currency | CNY |
TEYI Pharmaceutical Group Co. Ltd. is listed on the Shenzhen Stock Exchange and operates from Taishan, China. The company specializes in the development, production, and sale of traditional Chinese medicine and chemical agents, with a nationwide distribution network and an online presence at www.tczy.com.cn .
